Blood Testing Market by Products (Blood Collection, Blood Testing Instruments, Reagents & Consumables), Test Type (Basic Metabolic Panels, Complete Blood Count Tests, Complete Metabolic Panels), Sample Type, Application, End-User - Global Forecast 2025-20
Description
The Blood Testing Market was valued at USD 105.66 billion in 2024 and is projected to grow to USD 114.87 billion in 2025, with a CAGR of 9.10%, reaching USD 212.17 billion by 2032.
A succinct orientation to the contemporary blood testing environment highlighting technological momentum, clinical demand drivers, and operational priorities for diagnostic stakeholders
The blood testing landscape sits at the intersection of clinical necessity, technological innovation, and evolving health system demands, driven by a need for faster, more accurate, and more accessible diagnostic information. Recent advancements in instrument miniaturization, assay sensitivity, and digital data integration have accelerated the translation of laboratory science into actionable clinical workflows. Meanwhile, demographic shifts and the rising prevalence of chronic conditions have sustained demand for routine and specialized testing, prompting stakeholders to reassess procurement priorities, laboratory configurations, and service delivery models.
As stakeholders adapt, supply chain resilience and regulatory compliance have emerged as core strategic concerns. Laboratories and health systems are increasingly aligning investment decisions with long-term operational resilience, emphasizing interoperability of data systems, centralized versus decentralized testing trade-offs, and vendor relationships that support product lifecycle management. In response, instrument and reagent developers are directing R&D toward automation, reduced sample volumes, and integrated analytics to support faster clinician decision-making. Taken together, these trends position blood testing not merely as a clinical commodity, but as an expanding node of clinical insight that fuels precision medicine pathways and population health initiatives.
How digital integration, decentralization of care, and instrument miniaturization are reshaping testing pathways and creating new clinical and commercial imperatives
The landscape of blood testing is transforming under the combined influence of digital health, precision diagnostics, and evolving care delivery models that emphasize speed, decentralization, and actionable data. Point-of-care testing is converging with laboratory-grade performance as manufacturers refine miniaturized biochemical, hematology, and immunoassay platforms. Concurrently, software and data management solutions are maturing to enable seamless integration of test results into electronic health records and clinical decision support systems, thus increasing the clinical utility of individual assays.
At the same time, decentralized care and home-based monitoring are expanding the footprint of sample collection and testing beyond traditional hospital settings. This shift propels innovation in capillary blood collection devices, lancets, and low-volume assays that maintain analytical integrity while improving patient experience. Furthermore, heightened expectations around turnaround time and data transparency drive laboratories to adopt automation and robust quality control frameworks, reducing variability and empowering clinicians with near-real-time insights. Together, these transformative shifts are redefining how testing is procured, delivered, and consumed across the healthcare continuum.
Evaluating the cascading operational and procurement ramifications of recent tariff shifts and how supply chain strategies must adapt to preserve continuity and competitiveness
The introduction of new tariff measures originating from trade policy adjustments can exert multifaceted effects across the blood testing value chain, with cumulative impacts that unfold over procurement cycles and product life spans. When tariffs raise the landed cost of imported instruments, reagents, or consumables, laboratories and distributors must reassess supplier contracts and inventory strategies. This can accelerate efforts to regionalize supply chains, diversify sources, or negotiate longer-term price agreements that mitigate short-term cost volatility. At the same time, manufacturers exposed to tariff-driven cost increases may adjust product pricing, concentrate production domestically, or accelerate localization of component sourcing to preserve competitiveness and margin structure.
Beyond direct cost effects, tariffs can influence capital expenditure decisions and technology adoption timelines. Facilities evaluating instrument upgrades may postpone purchases to avoid price shocks or seek flexible financing to smooth acquisition costs. In parallel, procurement teams will likely increase emphasis on total cost of ownership, serviceability, and consumable dependencies when selecting platforms. Tariff dynamics also raise regulatory and compliance burdens where product origin labeling and customs documentation increase administrative overhead for suppliers and buyers alike. Ultimately, the cumulative impact of tariff changes is to emphasize supply chain agility, contractual flexibility, and strategic sourcing as essential risk management tools for diagnostic providers and suppliers in the period following policy shifts.
Detailed segmentation-driven insights linking products, test types, sample handling, clinical applications, and end-user environments to strategic product and commercial decisions
The market segmentation framework provides a granular lens through which to evaluate product design choices, service models, and adoption patterns, starting with a product-based breakdown that distinguishes Blood Collection, Blood Testing Instruments, Reagents & Consumables, and Software & Data Management Solutions. Within Blood Collection the distinctions among Blood Collection Tubes (BCTs), Capillary Blood Collection Devices, Lancets, and Syringes & Needles reflect differing user needs, regulatory pathways, and inventory dynamics that influence procurement cycles and clinical adoption. Likewise, the Blood Testing Instruments category separates Biochemical Analyzers, Coagulation Analyzers, Hematology Analyzers, and Immunoassay Analyzers, each representing unique performance characteristics and consumable ecosystems that shape vendor lock-in and service models.
Complementing product segmentation, test-type distinctions-Basic Metabolic Panels, Complete Blood Count Tests, Complete Metabolic Panels, and Electrolyte Panels-illuminate clinical demand patterns and throughput requirements that guide instrument configuration and assay selection. Sample type segmentation identifies practical considerations for specimen handling and analytical validation across Arterial Blood Samples, Capillary Blood Samples, Plasma/Serum Samples, and Venous Blood Samples, with implications for pre-analytical quality and patient experience. Application-focused segmentation highlights priority clinical areas such as Allergies, Autoimmune Diseases, Cancer and other hematologic disorders, Endocrine System Disorders, and Heart Diseases, each driving distinct assay portfolios and interpretive workflows. Finally, end-user segmentation differentiates operational environments-Blood Banks, Diagnostic Centers, Hospital & Clinics, and Pathology Labs-each with specific accreditation, throughput, and integration requirements that influence purchasing behavior and supplier relationships. Integrating these segmentation layers enables stakeholders to align product roadmaps, distribution strategies, and service offerings with clear clinical and operational use cases.
Regional dynamics and market access strategies that reconcile diverse regulatory, infrastructure, and procurement realities across the Americas, Europe Middle East & Africa, and Asia-Pacific
Regional dynamics exert powerful influence on adoption patterns, regulatory complexity, and supply chain architecture, beginning with the Americas where established clinical infrastructures and large hospital networks support rapid uptake of automation and integrated data solutions while encouraging consolidation among suppliers. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory regimes, reimbursement models, and infrastructure maturity that requires adaptable market entry strategies, localized regulatory navigation, and flexible service models to address heterogeneity in laboratory capability and procurement practices. Meanwhile, Asia-Pacific continues to combine high-growth demand in populous markets with substantial investment in domestic manufacturing capacity and policy initiatives that favor localization, creating opportunities for partnerships that transfer technology and support scale.
Across all regions, interoperability standards, data privacy rules, and clinical guidelines shape the pace and pattern of deployment for digital health components. Therefore, companies pursuing cross-region expansion must develop region-specific commercialization plans that account for differences in laboratory accreditation, clinician workflows, and public health priorities. Strategic choices around regional distribution centers, local technical support, and flexible training programs will determine the effectiveness of market penetration and the resilience of post-sales service models in the face of local regulatory and operational constraints.
Competitive landscape overview emphasizing innovation, strategic partnerships, and service excellence as critical differentiators for long-term leadership in blood diagnostics
Competitive dynamics in blood testing reflect a balance between established instrument developers, reagent specialists, and agile software providers that bring analytics and workflow orchestration capabilities. Market leaders pursue differentiated value through investments in automation, assay portfolio breadth, and service networks that reduce total cost of ownership and simplify laboratory workflows. Simultaneously, smaller innovators and specialized firms drive focused advances in assay sensitivity, point-of-care usability, and novel sample handling technologies that challenge incumbents to accelerate product iteration and partnership strategies.
Strategic collaborations between instrument manufacturers and software or data management providers are increasing, reflecting a recognition that integrated offerings enhance clinician utility and lock-in through digital ecosystems. In addition, alliances with regional distributors and contract manufacturers support faster market entry and localized service. Across competitive tiers, intellectual property management, regulatory track records, and the ability to demonstrate robust clinical validation remain differentiators that determine long-term adoption, while after-sales service quality and consumable availability continue to shape customer loyalty and renewal patterns.
Action-oriented strategic imperatives for industry leaders to reinforce supply chain resilience, advance integrated diagnostics, and accelerate clinical adoption through service excellence
Industry leaders should orient strategy toward supply chain resilience, clinical integration, and differentiated service models to capture emerging opportunities while mitigating systemic risks. Specifically, executives are advised to prioritize supplier diversification and nearshoring of critical components to reduce exposure to tariff volatility and logistical disruptions, while simultaneously investing in predictive procurement analytics to optimize inventory and reduce service interruptions. At the product level, advancing modular instrument architectures that support multi-analyte workflows and flexible consumable footprints will improve adaptability across end-user environments and lengthen platform lifecycles.
Equally important is the deep integration of software and data management capabilities to enhance result interpretation, automate quality assurance, and connect assays to clinical decision support. To accelerate adoption, companies should build comprehensive training and service offerings that reduce onboarding friction and demonstrate measurable improvements in turnaround time and error reduction. Finally, pursuing strategic partnerships with clinical networks and laboratories for real-world validation will strengthen credibility and support iterative product improvements that align with clinician workflow realities.
Methodological approach combining literature synthesis, primary stakeholder engagement, and multi-source validation to produce reliable insights for strategic decision making in diagnostics
The research methodology underpinning this analysis combined systematic literature review, targeted primary interviews, and multi-source data triangulation to ensure robust, actionable insights. The literature review synthesized peer-reviewed studies, regulatory guidance, clinical practice documentation, and technical white papers to establish a baseline of analytical performance characteristics and clinical utility. Primary research included structured interviews with laboratory directors, procurement leads, clinical pathologists, instrument engineers, and industry executives to capture on-the-ground perspectives on adoption drivers, pain points, and service expectations.
To validate qualitative findings, the study conducted scenario analyses around supply chain disruptions and tariff impacts, and performed comparative assessments of instrument architectures, consumable ecosystems, and digital integration capabilities. All findings underwent cross-validation against publicly available regulatory filings, clinical guideline updates, and professional society recommendations to ensure alignment with current practice. This multi-method approach prioritized transparency, reproducibility, and practical relevance for decision makers seeking to translate insights into procurement, product development, and partnership strategies.
Concise synthesis of diagnostic trends and strategic levers that will determine which blood testing solutions deliver sustained clinical impact and operational value
In conclusion, blood testing is in a period of constructive transformation driven by advances in instrumentation, digital integration, and shifting care delivery models that emphasize speed, accessibility, and actionable data. The interplay between product innovation, regulatory environments, and supply chain dynamics will determine which solutions achieve scale and sustain clinical impact. Laboratories and providers that prioritize interoperability, operational resilience, and clinician-centered workflows will derive the greatest benefit from next-generation diagnostic platforms.
Looking ahead, continued alignment between assay developers, instrument manufacturers, and software providers will be essential to translate technical improvements into measurable clinical outcomes. Stakeholders that combine disciplined operational planning with adaptive commercialization strategies will best navigate trade-offs introduced by policy changes and regional variation. Ultimately, the capacity to integrate diagnostics into broader care pathways will define value creation and set the trajectory for long-term improvements in patient care and system efficiency.
Note: PDF & Excel + Online Access - 1 Year
A succinct orientation to the contemporary blood testing environment highlighting technological momentum, clinical demand drivers, and operational priorities for diagnostic stakeholders
The blood testing landscape sits at the intersection of clinical necessity, technological innovation, and evolving health system demands, driven by a need for faster, more accurate, and more accessible diagnostic information. Recent advancements in instrument miniaturization, assay sensitivity, and digital data integration have accelerated the translation of laboratory science into actionable clinical workflows. Meanwhile, demographic shifts and the rising prevalence of chronic conditions have sustained demand for routine and specialized testing, prompting stakeholders to reassess procurement priorities, laboratory configurations, and service delivery models.
As stakeholders adapt, supply chain resilience and regulatory compliance have emerged as core strategic concerns. Laboratories and health systems are increasingly aligning investment decisions with long-term operational resilience, emphasizing interoperability of data systems, centralized versus decentralized testing trade-offs, and vendor relationships that support product lifecycle management. In response, instrument and reagent developers are directing R&D toward automation, reduced sample volumes, and integrated analytics to support faster clinician decision-making. Taken together, these trends position blood testing not merely as a clinical commodity, but as an expanding node of clinical insight that fuels precision medicine pathways and population health initiatives.
How digital integration, decentralization of care, and instrument miniaturization are reshaping testing pathways and creating new clinical and commercial imperatives
The landscape of blood testing is transforming under the combined influence of digital health, precision diagnostics, and evolving care delivery models that emphasize speed, decentralization, and actionable data. Point-of-care testing is converging with laboratory-grade performance as manufacturers refine miniaturized biochemical, hematology, and immunoassay platforms. Concurrently, software and data management solutions are maturing to enable seamless integration of test results into electronic health records and clinical decision support systems, thus increasing the clinical utility of individual assays.
At the same time, decentralized care and home-based monitoring are expanding the footprint of sample collection and testing beyond traditional hospital settings. This shift propels innovation in capillary blood collection devices, lancets, and low-volume assays that maintain analytical integrity while improving patient experience. Furthermore, heightened expectations around turnaround time and data transparency drive laboratories to adopt automation and robust quality control frameworks, reducing variability and empowering clinicians with near-real-time insights. Together, these transformative shifts are redefining how testing is procured, delivered, and consumed across the healthcare continuum.
Evaluating the cascading operational and procurement ramifications of recent tariff shifts and how supply chain strategies must adapt to preserve continuity and competitiveness
The introduction of new tariff measures originating from trade policy adjustments can exert multifaceted effects across the blood testing value chain, with cumulative impacts that unfold over procurement cycles and product life spans. When tariffs raise the landed cost of imported instruments, reagents, or consumables, laboratories and distributors must reassess supplier contracts and inventory strategies. This can accelerate efforts to regionalize supply chains, diversify sources, or negotiate longer-term price agreements that mitigate short-term cost volatility. At the same time, manufacturers exposed to tariff-driven cost increases may adjust product pricing, concentrate production domestically, or accelerate localization of component sourcing to preserve competitiveness and margin structure.
Beyond direct cost effects, tariffs can influence capital expenditure decisions and technology adoption timelines. Facilities evaluating instrument upgrades may postpone purchases to avoid price shocks or seek flexible financing to smooth acquisition costs. In parallel, procurement teams will likely increase emphasis on total cost of ownership, serviceability, and consumable dependencies when selecting platforms. Tariff dynamics also raise regulatory and compliance burdens where product origin labeling and customs documentation increase administrative overhead for suppliers and buyers alike. Ultimately, the cumulative impact of tariff changes is to emphasize supply chain agility, contractual flexibility, and strategic sourcing as essential risk management tools for diagnostic providers and suppliers in the period following policy shifts.
Detailed segmentation-driven insights linking products, test types, sample handling, clinical applications, and end-user environments to strategic product and commercial decisions
The market segmentation framework provides a granular lens through which to evaluate product design choices, service models, and adoption patterns, starting with a product-based breakdown that distinguishes Blood Collection, Blood Testing Instruments, Reagents & Consumables, and Software & Data Management Solutions. Within Blood Collection the distinctions among Blood Collection Tubes (BCTs), Capillary Blood Collection Devices, Lancets, and Syringes & Needles reflect differing user needs, regulatory pathways, and inventory dynamics that influence procurement cycles and clinical adoption. Likewise, the Blood Testing Instruments category separates Biochemical Analyzers, Coagulation Analyzers, Hematology Analyzers, and Immunoassay Analyzers, each representing unique performance characteristics and consumable ecosystems that shape vendor lock-in and service models.
Complementing product segmentation, test-type distinctions-Basic Metabolic Panels, Complete Blood Count Tests, Complete Metabolic Panels, and Electrolyte Panels-illuminate clinical demand patterns and throughput requirements that guide instrument configuration and assay selection. Sample type segmentation identifies practical considerations for specimen handling and analytical validation across Arterial Blood Samples, Capillary Blood Samples, Plasma/Serum Samples, and Venous Blood Samples, with implications for pre-analytical quality and patient experience. Application-focused segmentation highlights priority clinical areas such as Allergies, Autoimmune Diseases, Cancer and other hematologic disorders, Endocrine System Disorders, and Heart Diseases, each driving distinct assay portfolios and interpretive workflows. Finally, end-user segmentation differentiates operational environments-Blood Banks, Diagnostic Centers, Hospital & Clinics, and Pathology Labs-each with specific accreditation, throughput, and integration requirements that influence purchasing behavior and supplier relationships. Integrating these segmentation layers enables stakeholders to align product roadmaps, distribution strategies, and service offerings with clear clinical and operational use cases.
Regional dynamics and market access strategies that reconcile diverse regulatory, infrastructure, and procurement realities across the Americas, Europe Middle East & Africa, and Asia-Pacific
Regional dynamics exert powerful influence on adoption patterns, regulatory complexity, and supply chain architecture, beginning with the Americas where established clinical infrastructures and large hospital networks support rapid uptake of automation and integrated data solutions while encouraging consolidation among suppliers. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory regimes, reimbursement models, and infrastructure maturity that requires adaptable market entry strategies, localized regulatory navigation, and flexible service models to address heterogeneity in laboratory capability and procurement practices. Meanwhile, Asia-Pacific continues to combine high-growth demand in populous markets with substantial investment in domestic manufacturing capacity and policy initiatives that favor localization, creating opportunities for partnerships that transfer technology and support scale.
Across all regions, interoperability standards, data privacy rules, and clinical guidelines shape the pace and pattern of deployment for digital health components. Therefore, companies pursuing cross-region expansion must develop region-specific commercialization plans that account for differences in laboratory accreditation, clinician workflows, and public health priorities. Strategic choices around regional distribution centers, local technical support, and flexible training programs will determine the effectiveness of market penetration and the resilience of post-sales service models in the face of local regulatory and operational constraints.
Competitive landscape overview emphasizing innovation, strategic partnerships, and service excellence as critical differentiators for long-term leadership in blood diagnostics
Competitive dynamics in blood testing reflect a balance between established instrument developers, reagent specialists, and agile software providers that bring analytics and workflow orchestration capabilities. Market leaders pursue differentiated value through investments in automation, assay portfolio breadth, and service networks that reduce total cost of ownership and simplify laboratory workflows. Simultaneously, smaller innovators and specialized firms drive focused advances in assay sensitivity, point-of-care usability, and novel sample handling technologies that challenge incumbents to accelerate product iteration and partnership strategies.
Strategic collaborations between instrument manufacturers and software or data management providers are increasing, reflecting a recognition that integrated offerings enhance clinician utility and lock-in through digital ecosystems. In addition, alliances with regional distributors and contract manufacturers support faster market entry and localized service. Across competitive tiers, intellectual property management, regulatory track records, and the ability to demonstrate robust clinical validation remain differentiators that determine long-term adoption, while after-sales service quality and consumable availability continue to shape customer loyalty and renewal patterns.
Action-oriented strategic imperatives for industry leaders to reinforce supply chain resilience, advance integrated diagnostics, and accelerate clinical adoption through service excellence
Industry leaders should orient strategy toward supply chain resilience, clinical integration, and differentiated service models to capture emerging opportunities while mitigating systemic risks. Specifically, executives are advised to prioritize supplier diversification and nearshoring of critical components to reduce exposure to tariff volatility and logistical disruptions, while simultaneously investing in predictive procurement analytics to optimize inventory and reduce service interruptions. At the product level, advancing modular instrument architectures that support multi-analyte workflows and flexible consumable footprints will improve adaptability across end-user environments and lengthen platform lifecycles.
Equally important is the deep integration of software and data management capabilities to enhance result interpretation, automate quality assurance, and connect assays to clinical decision support. To accelerate adoption, companies should build comprehensive training and service offerings that reduce onboarding friction and demonstrate measurable improvements in turnaround time and error reduction. Finally, pursuing strategic partnerships with clinical networks and laboratories for real-world validation will strengthen credibility and support iterative product improvements that align with clinician workflow realities.
Methodological approach combining literature synthesis, primary stakeholder engagement, and multi-source validation to produce reliable insights for strategic decision making in diagnostics
The research methodology underpinning this analysis combined systematic literature review, targeted primary interviews, and multi-source data triangulation to ensure robust, actionable insights. The literature review synthesized peer-reviewed studies, regulatory guidance, clinical practice documentation, and technical white papers to establish a baseline of analytical performance characteristics and clinical utility. Primary research included structured interviews with laboratory directors, procurement leads, clinical pathologists, instrument engineers, and industry executives to capture on-the-ground perspectives on adoption drivers, pain points, and service expectations.
To validate qualitative findings, the study conducted scenario analyses around supply chain disruptions and tariff impacts, and performed comparative assessments of instrument architectures, consumable ecosystems, and digital integration capabilities. All findings underwent cross-validation against publicly available regulatory filings, clinical guideline updates, and professional society recommendations to ensure alignment with current practice. This multi-method approach prioritized transparency, reproducibility, and practical relevance for decision makers seeking to translate insights into procurement, product development, and partnership strategies.
Concise synthesis of diagnostic trends and strategic levers that will determine which blood testing solutions deliver sustained clinical impact and operational value
In conclusion, blood testing is in a period of constructive transformation driven by advances in instrumentation, digital integration, and shifting care delivery models that emphasize speed, accessibility, and actionable data. The interplay between product innovation, regulatory environments, and supply chain dynamics will determine which solutions achieve scale and sustain clinical impact. Laboratories and providers that prioritize interoperability, operational resilience, and clinician-centered workflows will derive the greatest benefit from next-generation diagnostic platforms.
Looking ahead, continued alignment between assay developers, instrument manufacturers, and software providers will be essential to translate technical improvements into measurable clinical outcomes. Stakeholders that combine disciplined operational planning with adaptive commercialization strategies will best navigate trade-offs introduced by policy changes and regional variation. Ultimately, the capacity to integrate diagnostics into broader care pathways will define value creation and set the trajectory for long-term improvements in patient care and system efficiency.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid growth of at-home blood testing kits with smartphone connectivity for real-time results
- 5.2. Integration of artificial intelligence algorithms in blood testing workflows for predictive analytics
- 5.3. Emerging use of microfluidic lab-on-a-chip platforms to enable faster and low-volume blood assays
- 5.4. Increasing regulatory approvals for novel molecular blood biomarkers in early disease detection
- 5.5. Expanding partnerships between blood testing companies and pharmaceutical firms for companion diagnostics
- 5.6. Rising demand for multiplex blood tests that can simultaneously measure multiple biomarkers in a single sample
- 5.7. Advancements in nano-enabled biosensors for ultrasensitive detection of blood-based disease markers
- 5.8. Shift towards decentralized testing models driven by remote patient monitoring and wearable blood sampling
- 5.9. Increasing focus on cost-effective blood testing solutions for emerging markets in Asia Pacific and Latin America
- 5.10. Development of blood-based liquid biopsy assays for early cancer detection and monitoring minimal residual disease
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Blood Testing Market, by Products
- 8.1. Blood Collection
- 8.1.1. Blood Collection Tubes (BCTs)
- 8.1.2. Capillary Blood Collection Devices
- 8.1.3. Lancets
- 8.1.4. Syringes & Needles
- 8.2. Blood Testing Instruments
- 8.2.1. Biochemical Analyzers
- 8.2.2. Coagulation Analyzers
- 8.2.3. Hematology Analyzers
- 8.2.4. Immunoassay Analyzers
- 8.3. Reagents & Consumables
- 8.4. Software & Data Management Solutions
- 9. Blood Testing Market, by Test Type
- 9.1. Basic Metabolic Panels
- 9.2. Complete Blood Count Tests
- 9.3. Complete Metabolic Panels
- 9.4. Electrolyte Panels
- 10. Blood Testing Market, by Sample Type
- 10.1. Arterial Blood Samples
- 10.2. Capillary Blood Samples
- 10.3. Plasma/Serum Samples
- 10.4. Venous Blood Samples
- 11. Blood Testing Market, by Application
- 11.1. Allergies
- 11.2. Autoimmune Diseases
- 11.3. Cancer/Noncancerous Blood Disorders
- 11.4. Endocrine System Disorders
- 11.5. Heart Diseases
- 12. Blood Testing Market, by End-User
- 12.1. Blood Banks
- 12.2. Diagnostic Centers
- 12.3. Hospital & Clinics
- 12.4. Pathology Labs
- 13. Blood Testing Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Blood Testing Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Blood Testing Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. A. Menarini Diagnostics s.r.l.
- 16.3.2. Abbott Laboratories
- 16.3.3. ACON Laboratories, Inc.
- 16.3.4. ARKRAY, Inc.
- 16.3.5. B. Braun Melsungen AG
- 16.3.6. Becton Dickinson & Company
- 16.3.7. Bio-Rad Laboratories Inc.
- 16.3.8. BioMérieux SA
- 16.3.9. Danaher Corporation
- 16.3.10. F. Hoffmann-La Roche AG
- 16.3.11. Johnson & Johnson Services, Inc.
- 16.3.12. Medtronic PLC
- 16.3.13. Merck KGaA
- 16.3.14. Nipro Corporation
- 16.3.15. Nova Biomedical Corporation
- 16.3.16. Ortho Clinical Diagnostics, Inc.
- 16.3.17. Quest Diagnostic
- 16.3.18. Randox Laboratories Ltd.
- 16.3.19. Siemens AG
- 16.3.20. Terumo Corporation
- 16.3.21. Thermo Fisher Scientific, Inc.
- 16.3.22. Trinity Biotech PLC
- 16.3.23. Trividia Health, Inc.
- 16.3.24. Ypsomed AG
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
